Physician benefit-risk preferences for non-metastatic castration-resistant prostate cancer treatment (nmCRPC). Srinivas, S., Mohamed, A. F., Appukkuttan, S., Botteman, M., Ng, X., Joshi, N., Horodniceanu, E., Waldeck, R., Simmons, S. J. AMER SOC CLINICAL ONCOLOGY. 2019

View details for DOI 10.1200/JCO.2019.37.15_suppl.e16610

View details for Web of Science ID 000487345801626